The contraceptives market has a strong pipeline supporting growth in the market and attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Teva, Watson, Bayer and Merck have active contraceptive pipelines. One of the major activities in the market at present is the development of generic versions of off patent drugs. The entry of these generic versions will boost the oral contraceptive market and thereby bring about further rises in the hormonal contraceptives market in the coming years. The rapid entry of new players is set to intensify competition in this market. Also, the presence of a highly active pipeline is an indicator of strong market competition in the future.

‘In 2009, the global contraceptives market was estimated at $11.2 billion, and achieved a CAGR of 7% between 2001 and 2009. The market is forecast to record revenues of $14.5 billion by 2016, growing at a CAGR of 4% between 2009 and 2016.’

GBI Research’s report ‘Contraceptive Market to 2016 -Demand for Long Acting Birth Control Pills Encourages Growth in Hormonal Contraceptives Market’ provides a detailed insight in to the contraceptive market to 2016. In-depth analyses on the global contraceptive treatment usage patterns and the contraceptive markets in key geographies, namely the US, top five EU countries and Japan are covered in the report. Details about contraceptive R&D pipelines and potential future blockbuster products are also provided. The report also explores the competitive landscape, with a competitive analysis of the top companies in the market and a key trend analysis of mergers and acquisitions and licensing agreements in the contraceptives market.

The cancer biomarkers pipeline has a total of 274 tests under various stages of development in various cancer areas, dominated by breast cancer, prostate cancer and colorectal cancer. These three cancers share a total of almost 60% of the pipeline. The other two major cancer types in the biomarkers pipeline are ovarian cancer and lung cancer with shares of 14% each. The global cancer biomarker market was estimated to be $3.6 billion in 2007 and is expected to grow at a CAGR of 6.3% to reach $6.3 billion by 2016.

Growth of Personalised Medicine and Strong Regulatory Support Will Drive the Future Growth for Biomarkers in Cancer Research

The growth of personalised medicines and the strong support from regulatory agencies such as the FDA will be the two major factors that will drive the demand for biomarkers in cancer research. Personalised medicines are gaining popularity due to their ability to provide customised treatment to patients based on their genetic and medical profile. As personalised medicine gains more importance and popularity and with strong support from regulatory agencies such as the FDA, the demand for biomarkers is expected to increase. The FDA has been strongly advocating the use of biomarkers in drug discovery research as it has also formed associations that work towards the classification and discovery of exploratory biomarkers, and for qualifying and validating them for use in the clinical process. It is expected that the FDA will provide faster, more flexible, simpler and more practical regulatory norms and validation procedures for biomarkers.